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Abstract
TWEAK is a member of the TNF superfamily of cytokines that contribute to kidney tubulointerstitial injury. It has previously
been reported that TWEAK induces transient nuclear translocation of RelA and expression of RelA-dependent cytokines in
renal tubular cells. Additionally, TWEAK induced long-lasting NFkB activation suggestive of engagement of the non-
canonical NFkB pathway. We now explore TWEAK-induced activation of NFkB2 and RelB, as well as expression of CCL21, a T-
cell chemotactic factor, in cultured murine tubular epithelial cells and in healthy kidneys in vivo. In cultured tubular cells,
TWEAK and TNFa activated different DNA-binding NFkB complexes. TWEAK-induced sustained NFkB activation was
associated with NFkB2 p100 processing to p52 via proteasome and nuclear translocation and DNA-binding of p52 and RelB.
TWEAK, but not TNFa used as control), induced a delayed increase in CCL21a mRNA (3.561.22-fold over control) and CCL21
protein (2.560.8-fold over control), which was prevented by inhibition of the proteasome, or siRNA targeting of NIK or RelB,
but not by RelA inhibition with parthenolide. A second NFkB2-dependent chemokine, CCL19, was upregulates by TWEAK,
but not by TNFa. However, both cytokines promoted chemokine RANTES expression (3-fold mRNA at 24 h). In vivo, TWEAK
induced nuclear NFkB2 and RelB translocation and CCL21a mRNA (1.560.3-fold over control) and CCL21 protein (1.660.5-
fold over control) expression in normal kidney. Increased tubular nuclear RelB and tubular CCL21 expression in acute kidney
injury were decreased by neutralization (260.9 vs 1.360.6-fold over healthy control) or deficiency of TWEAK (260.9 vs
0.860.6-fold over healthy control). Moreover, anti-TWEAK treatment prevented the recruitment of T cells to the kidney in
this model (4.161.4 vs 1.861-fold over healthy control). Our results thus identify TWEAK as a regulator of non-canonical
NFkB activation and CCL21 expression in tubular cells thus promoting lymphocyte recruitment to the kidney during acute
injury.
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Introduction
Acute kidney injury (AKI) and progressive loss of renal function
are associated with interstitial inflammation and tubular injury [1].
Infiltration by leukocytes depends on the local expression of
inflammatory cytokines and chemokines. Tubular epithelial cells
release an array of cytokines in response to various immune and
non-immune factors, contributing to attraction of inflammatory
cells to the kidney [2,3]. Members of the TNF superfamily regulate
several cell responses, including proliferation, differentiation, cell
death and inflammation [4]. Some of these cytokines, such as TNF
and FasL, have been extensively studied in kidney diseases and
shown to be involved in renal damage [5–8]. More recently, Tumor
necrosis factor-like weak inducer of apoptosis (TWEAK, TNFSF12)
has been implicated in glomerular and tubulointerstitial inflamma-
tory responses [9–13], cell death in the presence of additional
inflammatory mediators, [10,11] and cell proliferation in the
absence of such mediators [14–17]. TWEAK mediates its biologic
activitities by signaling via its receptor Fibroblast growth factor-
inducible 14 (Fn14) [9,11]. It was previously shown that TWEAK-
induced chemokine secretion in tubular cells was mediated by the
RelA NFkB subunit [9]. Additionally, a sustained NFkB activation
of unknown significance was noted, consistent with the NFkBn o n -
canonical pathway activation [9]. In this pathway, the NFkB-
inducing kinase activity (NIK) is required for the phosphorylation/
ubiquitination and proteasomal processing of the IkB protein
NFkB2 p100 to NFkB2 p52 [18]. NFkB2 p52/RelB dimer
translocates to the nucleus and activates transcription of specific
gene targets [19]. Only a few cytokines are able to engage this
pathway, including B-cell activating factor (BAFF) [20,21], CD40
ligand [22], and receptor activator of NF-kappa-B ligand (RANKL)
[23], but not TNF [18]. Non-canonical activation of NFkB2
leads to transcription of a set of genes different from those regu-
lated by canonical NFkB activation [19]. Following lymphotoxin
(LT)-b receptor (LTbR) ligation in splenocytes NFkB2 targets
include CC chemokine ligand 21/secondary lymphoid chemokine
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8955(CCL21)/(SLC), EBI-1-ligand chemokine (ELC/CCL19), B lym-
phocyte chemoattractant (BLC/CXCL13), stromal cell-derived
factor-1 a (SDF-1-a/CXCL12) and BAFF [19]. However, the
regulation and targets of the non-canonical pathway in renal cells
are poorly understood. TWEAK was reported to activate NFkB2 in
fibroblasts, but the functional consequences were not studied and
whether this pathway is active in epithelial and, specifically, in renal
epithelial cells, is unknown [24]. Different cell types activate NFkB
in a different manner when exposed to the same stimulus [25].
CCL21 is T-cell chemotactic factor that has been recently related to
renal tubulointerstitial injury [26]. However the factors that
contribute to CCL21 upregulation in renal tubulointerstitial injury
are poorly characterized.
We now report that TWEAK activates NFkB2 and RelB and
induces the expression of CCL21a mRNA and CCL21 protein in
cultured murine tubular epithelial cells and in healthy kidneys and
that TWEAK antagonism reduces tubular CCL21 and lympho-
cyte T infiltration in folic acid-induced AKI. To our knowledge
this is the first report of non-canonical NFkB pathway regulators
and targets in tubular cell injury.
Methods
Cells and Reagents
MCT murine proximal tubular epithelial cells were cultured in
RPMI 1640, (GIBCO, Grand Island, NY, USA), 10% decom-
plemented fetal bovine serum, 2 mM glutamine, 100 U/mL
penicilin and 10 mg/mL streptomycin, in 5% CO2 at 37uC.[9].
Recombinant human soluble TWEAK (Alexis, La ¨ufelfingen,
Switzerland) was used at 100 ng/ml and murine TNFa (Im-
mugenex. Los Angeles, CA) at 30 ng/mL based on prior TWEAK
and TNFa dose-response induction of cytokine production and
cell death induction in MCT cells [9,27]. The NFkB inhibitor
parthenolide (Sigma, St. Louis, MO) was used at 10 mM, the
proteasome inhibitor MG132 (Calbiochem, La Jolla, CA) at
20 mM, the proteasome inhibitor lactacystin (Sigma) at 10 mm.
Western Blot
Samples of tissue and cells were homogenized in lysis buffer were
separated by 10–12% SDS-PAGE under reducing conditions [9].
Primary antibodies were rabbit polyclonal anti-p100/52 (1:500, a
gift of Helen Cooper), rabbit polyclonal anti-RelB (1:500, Santa
Cruz Biotechnology, CA), rabbit polyclonal anti IkBa (1:500,
Santa Cruz Biotechnology), rabbit polyclonal anti IkBb (1:500,
Santa Cruz Biotechnology), rabbit polyclonal anti phospho-IKKa
(1:500, Santa Cruz Biotechnology), rabbit polyclonal anti-CCL21
(1:500, Santa Cruz Biotechnology). Blots were then probed with
anti-a-tubulin (1:2000, Sigma) for total proteins and anti-lamin B
(1:500, Santa Cruz Biotechnology) for nuclear proteins and levels of
expression were corrected for minor differences in loading.
Quantitative Reverse Transcription-Polymerase Chain
Reaction
One mg RNA isolated by Trizol (Invitrogen, UK) was reverse
transcribed with High Capacity cDNA Archive Kit and real-time
PCR was performed on a ABI Prism 7500 PCR system (Applied
Biosystems, Foster City, CA) using the DeltaDelta Ct method.
Expression levels are given as ratios to GAPDH. Pre-developed
primer and probe assays were from Applied [9].
Electrophoretic Mobility Shift Assay (EMSA)
Cells were resuspended in buffer A (10 mmol/L HEPES,
pH 7.8, 15 mmol/L KCl, 2 mmol/L MgCl2, 1 mmol/L PMSF,
0.1 mmol/L EDTA, and 1 mmol/L DDT) and homogenized.
Nuclei and cytosolic fractions were separated by centrifugation at
10006g 10 min. Nuclei (pellet) were washed twice in buffer A
and resuspended in the same buffer, with a final concentration
of 0.39 mol/L KCl. Nuclei were extracted for 1 h at 4uC
and centrifuged at 100,0006g 30 min. Supernatants containing
nuclei were dialyzed in buffer C (50 mmol/L HEPES, pH 7.8,
50 mmol/L KCl, 10% glycerol, 1 mmol/L PMSF, 0.1 mmol/L
EDTA, and 1 mmol/L DDT) and then cleared by centrifugation
and stored at 280uC. The protein concentration was determined
by the bicinchoninic acid method. EMSA was carried out as
previously described [9]. For supershift assays, nuclear extracts
were incubated with 1 mg anti-RelA, anti-RelB, or anti-p52
antibody, all from Santa Cruz Biotechnology, for 1 h at 37uC
before incubation with the labeled probe.
ELISA-Based NFkB Assay
Cells were stimulated with 100 ng/mL TWEAK for different
time periods. In some cases cells were pre-treated with
parthenolide or lactacystin 1 hour before TWEAK addition.
RelA, RelB and p52 subunits in nuclear extract were measured by
their binding to an oligonucleotide containing the NFkB consensus
site using TransAM NFkB Family Kit (Active Motif, Carlsbad,
CA).
siRNA Transfection
Cells were seeded at a 3610
5 in 6-wells plates and transfected
on the following day with 20 nM siRNA oligonucleotides by using
lipofectamine reagent (Invitrogen). After 72 h, the transfected cells
were treated with 100 ng/mL TWEAK for 24 h and harvested for
Western blot analysis. siRNA were synthesized by Santa Cruz
Biotechnology.
Confocal Microscopy
Cells plated onto Labtek
TM slides were fixed in 4% parafor-
maldehyde for 10 min and ermeabilized in 0.2% Triton X-100/
PBS for additional 10 min, washed in PBS and incubated with
rabbit polyclonal anti-RelB (1:75, Santa Cruz Biotechnology),
rabbit polyclonal anti-p100/p52 (1:50, a gift of Helen Cooper)
followed by FITC secondary antibody (1:200, Sigma). Nuclei were
counterstained with propidium iodide. Cells were analysed by
confocal microscopy.
Gene Expression Arrays
One mg RNA isolated by Trizol (Invitrogen UK) was reverse
transcribed with High Capacity cDNA Archive Kit (Applied
Biosystems). The resulting cDNA (0.5 ng) was added to the 2x
Universal PCR Master Mix (Applied Biosystems). Aliquots of the
mixture were placed into each well of a card with 384 wells. This
product has 96 TaqManH Gene Expression Assays loaded in
singletons into the array’s 384 wells, that include primer sets for 92
mouse genes known to have implications in immune response plus
four housekeeping genes (TaqManH Mouse Immune Array,
Applied Biosystems). Real-time PCR was performed with a
7900HT Fast Real-Time PCR System (Applied Biosystems).
Finally, data were analyzed based on the DDCt method with
normalization of the raw data to the four housekeeping genes.
Animal Model
Studies were conducted in accordance with the NIH Guide for
the Care and Use of Laboratory Animals. C57/BL6 mice (12- to
14-week-old)(IFFA-CREDO, Barcelona, Spain) were treated i.p.
with 0.75 mg/mouse of TWEAK or saline vehicle (200 ml 0.9%
NaCl). Mice were killed 4 h (n=6) or 24 h (n=7) after injection.
TWEAK and NFkB2 Pathway
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experiments, when TWEAK exhibited optimal activity at
10–100 ng/mL, assuming an extracellular volume of 7.5 mL/
mouse and was previously shown to induce biological responses in
kidneys [9].
Folic acid nephropathy is a classical model of AKI [9,28–30].
C57/BL6 mice (12- to 14-week-old) received a single i.p. injection
of folic acid (Sigma) 250 mg/kg in 0.3 M sodium bicarbonate or
vehicle and mice were killed 24 h later [9]. Mice were dosed ip
with either 200 mg neutralizing anti-TWEAK mAb (clone P2D10,
Biogen Idec) [9] or 200 mg isotype IgG (mouseIgG2a, clone P1.17,
Biogen Idec) (n=6 per group). Animals received the mAb
treatments one-day prior to the folic acid injection. In a second
set of experiment, TWEAK knock out (KO) (Biogen Idec)[11]
mice on the C57Bl/6 background strain received i.p. folic acid
injection and they were killed 24 h later. The kidneys were
perfused in situ with cold saline before removal. One kidney was
snap-frozen in liquid nitrogen for RNA and protein studies and the
other fixed and paraffin embedded.
Immunohistochemistry
Immunohistochemistry was carried out as previously described
on paraffin-embedded 5 mm tissue sections [9]. Primary antibodies
were rabbit polyclonal anti-RelB (1:50, Santa Cruz), rabbit
polyclonal anti-p100/p52 (1:20, Santa Cruz), goat polyclonal
anti-CCL21 (1:90, R&D Systems, Minneapolis, MN). Sections
were counterstained with Carazzi’s hematoxylin. Negative controls
included incubation with a non-specific immunoglobulin of the
same isotype as the primary antibody. CCL21 staining was
evaluated by a quantitative scoring system using Image Pro Plus
Software (Media cybernetics, Bethesda, MD) in 10 randomly
chosen fields (20x) per kidney [9]. Samples were examined in a
blinded manner.
CD3 cells were stained with rabbit polyclonal anti-CD3 (1:300,
Dako Diagnostics, Barcelona, Spain), using Dako REAL
TM
EnVision
TM kit (Dako). The total number of CD3 positive
lymphocytes was quantitated in 20 randomly chosen fields (x40)
using Image-Pro Plus software. Samples were examined in a
blinded manner.
Statistics
Statistical analysis was performed using SPSS 11.0 statistical
software. Results are expressed as mean 6 SEM. Significance at
the p,0.05 level was assessed by Student’s t test for two groups of
data and ANOVA for three of more groups.
Results
TWEAK Induces NFkB2 Processing, p52/RelB Nuclear
Translocation and DNA-Binding in Renal Tubular
Epithelial Cells
We had previously described a delayed NFkB activation
induced by TWEAK in tubular cells (Figure 1A) [9]. Supershift
assays demonstrated the presence of RelB and p52 in TWEAK-
induced DNA binding NFkB complexes, while RelA was present
in both TNFa- and TWEAK-induced complexes (Figure 1B).
The RelA and RelB/p52 containing bands migrated very close,
similar to results reported in HT29 cells following LTbR ligation
[19]. The addition of the p52 antibody resulted in the appearance
of an even faster migrating complex. This faster migration has
been previously been described in HT29 cells [31]. These results
indicate that TWEAK induces non-canonical, sustained NFkB
activation in tubular cells. On the other hand, in whole cell protein
extracts TWEAK decreased NFkB2 p100 and increased the
amount of its degradation product p52 in a time-dependent
manner (Figure 1C). This was not observed with TNFa
(Figure 1D). In fact, TNFa induces the expression of p100.
These results suggest that TWEAK, but not TNFa, could activate
NFkB2.
TWEAK reportedly induced early and transient nuclear
translocation of RelA in tubular cells [9]. We now show that
TWEAK induces a progressive time-dependent increment in
nuclear p52 and RelB, as assessed by ELISA of nuclear extracts
(Figure 2A) Western blot (Figure 2C), and confocal microscopy
(Figure 3C). An ELISA of nuclear NFkB subunits confirmed the
early and transient nature of the increase in nuclear RelA and the
progressive increase in nuclear RelB and p52 in MCT cells treated
with TWEAK (Figure 2A), whereas TNFa only induces nuclear
RelA translocation (Figure 2B). In MCT cells TWEAK induces
degradation of IkBa and IkBb (Figure 2D), and this was
temporarily associated with translocation of the RelA subunit of
NFkB from the cytoplasm to the nucleus [9]. The activation of the
IKKa subunit of the IKK complex is necessary for NFkB2
activation via the non-canonical pathway [18]. In this regard, we
observed by western blot that TWEAK induces IKKa phosphor-
ylation (Figure 2E).
Proteasome Activity Mediates TWEAK-Induced Non-
Canonical NFkB2 Activation
The proteasome inhibitors, MG132 and lactacystin reduced the
processing of p100 to p52 induced by TWEAK (Figure 3A).
However, parthenolide, a sesquiterpeno lactone that inhibits RelA
activation by preventing the degradation of IkB-a [9,32] did not
prevent p100 processing (Figure 3A). Parthenolide inhibits
nuclear translocation of RelA, as previously observed by confocal
microscopy and Western blot [9] while not modulating the nuclear
translocation of RelB and p52 as assessed by ELISA of nuclear
extract and confocal microscopy (Figure 3B,C). However, the
proteasome inhibitor lactacystin inhibited nuclear translocation of
RelB and p52, as assessed by ELISA of nuclear extracts and
confocal microscopy (Figure 3B,C).
TWEAK-Induced NFkB2 Activation Increases CCL21a
Expression in Renal Tubular Cells
CCL21 was previously reported to be a gene target of the non-
canonical NFkB2 pathway in splenocytes [19,33]. We selected
CCL21 as a potential target of NFkB2 activation in renal cells
because it modulates T cell recruitment and CCL21 has recently
been reported to play a role in tubulointerstitial injury [26].
Additionally, the pathways that regulate its expression in the kidney
are unknown. As previously reported basal CCL21a mRNA levels
were 40-fold higher in control spleen than in control kidney (not
shown) [34]. TWEAK induced the expression of CCL21a mRNA
in cultured tubular cells. The time-course of CCL21a stimulation
paralleled thatofRelB/p52accumulationinnuclei,increasingupto
24 h (Figure 4A). We used RANTES as a TNF-inducible control.
At the protein level, TWEAK, but not TNFa, induced the
expression of the CCL21 cytokine (Figure 4B). Unsupervised
hierarchical cluster analysis of an array of 94 immune response-
related genes did not disclose differences between TNF and
TWEAK treated cells at either 4 or 24 h: samples stimulated with
either cytokine clustered together and could not be separated.
However, induction of CCL19 mRNA, a known target of NFkB2
[19,35], was only observed in TWEAK stimulated cells. Induction
of CCL19 mRNA with a time-course consistent with the RelB/p52
accumulation in nuclei by TWEAK, but not by TNF, was then
confirmed by qRT-PCR (Figure 4A).
TWEAK and NFkB2 Pathway
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translocation and thus, canonical NFkB activation [9,32]. Parthe-
nolide did not prevent the CCL21a up-regulation induced by
TWEAK (Figure 4C) suggesting that RelA does not mediate its
transcription. RANTES is a RelA target with a delayed pattern of
mRNA expression induction by inflammatory mediators, due to a
delayed access ofRelAto its encoding DNA [36]. Wehad previously
observed that TWEAK increases the expression of RANTES in a
temporal pattern similar to CCL21, that is delayed with respect to
the induction of other bone fide RelA targets such as MCP-1 [9], we
now confirmed this observation (Figure 4A). Parthenolide prevent-
ed TWEAK induction of RANTES mRNA, as previously reported
in detail [9], but did not modulate CCL21 expression (Figure 4C).
By contrast, lactacystin prevented CCL21a, but not RANTES
expression induced by TWEAK (Figure 4D).
The non-canonical NFkB pathway requires NFkB-inducing
kinases (NIK) activation and the formation of RelB/p52
complexes [18]. In this regard, siRNA targeting of either RelB
or NIK (Figure 5A) prevented CCL21 upregulation in cultured
tubular cells (Figure 5B).
Figure 1. Different DNA-binding NFkB complexes induced by TWEAK and TNFa in renal tubular cells. A) Time-course of NFkB activation
in MCT cells treated with 100 ng/mL TWEAK for indicated time periods. Representative EMSA of four independent experiments. B) Supershift analysis
of nuclear extracts from tubular cells treated with TWEAK or TNFa for 24 h. Bands were further separated by the use of a 3% acrylamide gel. Complex
1 consists of two bands (black arrowheads), one containing RelA, which is shared by both cytokines, and another containing RelB and p52, present
only in TWEAK-stimulated cells. Bands disappearing in the presence of antibodies marked by empty arrowheads. Representative EMSA of three
independent experiments. C,D) Tubular cell lysates were analyzed by Western blot probed with anti-p100/p52. (C) TWEAK time-response. Mean 6
SEM of four independent experiments. *p,0.001 vs control; **p,0.0001 vs control. (D) TNFa time-response. Mean 6 SEM of three independent
experiments. *p,0.02 vs control; **p,0.008 vs control.
doi:10.1371/journal.pone.0008955.g001
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Lymphocyte Infiltration
In vivo TWEAK administration to healthy control mice
promotes the nuclear translocation of RelB and p52 in tubular
cells (Figure 6). Consistent with the cell culture data, TWEAK
increases both CCL21a mRNA and protein expression in healthy
kidneys at 24 h but not at 41 h (Figure 7A,B). Furthermore
CCL21 protein was localized to tubular cells (Figure 7C,D) As
previously published, TWEAK did not modify serum creatinine
levels and only caused mild signs of tubular injury, but not cell
death, when administered to healthy mice [9].
Folic acid-induced AKI shares many of the features of human
AKI, including tubular cell death and proliferation, tubulointer-
stitial inflammation and delayed fibrosis [9,28–30]. We had
previously observed a key role for TWEAK in tubulointerstitial
inflammation in this model, as TWEAK and Fn14 expression by
tubular cells is increased (by 30% and 3-fold as assessed by
Western blot at 24 h) and TWEAK targeting by anti-TWEAK
antibodies decreased inflammation and preserved renal function
[9,10,37]. We now report RelB and p52 nuclear translocation,
whole kidney CCL21a mRNA upregulation and tubular cell
expression of CCL21 protein 24 h following induction of AKI
Figure 2. Nuclear translocation of p52 and RelB in TWEAK-stimulated tubular cells. A, B) Temporal pattern of nuclear translocation of
RelA, RelB and p52 in tubular cells stimulated with TWEAK, (A), or TNFa (B). ELISA of nuclear proteins binding to an oligonucleotide containing the
NFkB consensus site. C) Tubular cells were stimulated with 100 ng/mL TWEAK and nuclear cell lysates obtained at various time points were analyzed
by Western blot for p52 and RelB. Representative Western blot and densitometric quantification. Mean 6 SEM of four independent experiments.
*p,0.04 vs control; #p,0.009 vs control. No significant differences were observed between controls at different time points and they were grouped.
D) TWEAK induces degradation of the inhibitory subunits IkBa and IkBb, in a time-course consistent with canonical NFkB pathway activation.
Representative western blot of three independent experiments. E) TWEAK induces phosporylation of IKKa subunit of IKK complex. Representative
Western blot and quantification of three independent experiments. Mean 6 SEM of three experiments. *p,0.05 vs control.
doi:10.1371/journal.pone.0008955.g002
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PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8955Figure 3. Proteasome activity are required for TWEAK-induced p100 processing. A) Tubular cells pre-treated with 10 mM parthenolide,
10 mM lactacystin or 20 mM MG132 were stimulated with 100 ng/ml TWEAK for 6 h. Mean 6 SEM of four experiments. *p,0.0001 vs control;
#p,0.02 vs TWEAK alone. Representative Western blots and quantification. B) Treatment with parthenolide does not prevent the nuclear
translocation of RelB or p52, whereas lactacystin prevents this nuclear translocation. ELISA of nuclear proteins binding to an oligonucleotide
containing the NFkB consensus site. C) Confocal microscopy. TWEAK induced nuclear translocation of RelB and p52 (both in green) at 3 h and 24 h
that was prevented by lactacystin but not by parthenolide. TNFa does not induce RelB and p52 (both in green) nuclear translocation at 24 h.
Propidium iodide is shown in orange. Note nuclear yellowish color in merged images when the proteins translocate to the nucleus (arrows).
Representative pictures of three independent experiments.
doi:10.1371/journal.pone.0008955.g003
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bodies or absence of TWEAK in TWEAK2/2 mice prevented
the RelB and p52 nuclear translocation and the increased
CCL21 expression in AKI (Figure 8, 9). In vivo, CCL21 is
chemotactic for T lymphocytes [33,34], and recently, TWEAK
was shown to induce kidney infiltration by T cells [38]. In this
regard, we observed increased renal interstitial CD3 positive
lymphocytes in AKI at 24 h, and neutralization of TWEAK and
TWEAK absence decreased the number of CD3 lymphocyte
(Figure 10).
Figure 4. TWEAK induces the expression of NFkB2 targets, CCL21 and CCL19, in tubular cells. A) Time-dependent increase in CCL21a,
CCL19 and RANTES mRNA expression in tubular cells treated with 100 ng/mL TWEAK or 30 ng/ml TNFa. Real time RT-PCR. Mean 6SEM of four
independent experiments. *p,0.04 vs control. B) Time-dependent increase in CCL21 protein expression in tubular cells treated with 100 ng/mL
TWEAK or 30 ng/mL TNFa. Mean 6SEM of four independent experiments. *p,0.03 vs control. C) Parthenolide (PTN) does not prevent TWEAK-
induced CCL21a mRNA up-regulation at 24 h. Real time RT-PCR. Mean 6SEM of four experiments. *p,0.04 vs control; #p,0.04 vs TWEAK alone. D)
Lactacystin prevents TWEAK-induced CCL21a mRNA up-regulation at 24 h. Real time RT-PCR. Mean 6SEM of four experiments. *p,0.04 vs control;
#p,0.03 vs TWEAK alone.
doi:10.1371/journal.pone.0008955.g004
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PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8955Figure 5. RelB and NIK down-regulation by siRNA reduces TWEAK-induced CCL21 expression in tubular cells. A) RelB and NIK protein
levels are efficiently down-regulation by siRNA. Tubular cells were transfected with either a siRNA oligonucleotide targeting RelB, NIK or scrambled
control. RelB and NIK expression was assessed 72 hours after transfection by Western blot. Representative Western blot of four independent
experiments. B) Tubular cells transfected 72 h earlier were treated with TWEAK for 24 h. RelB or NIK siRNA targeting prevented CCL21 upregulation.
Representative Western blot and quantification. Mean 6 SEM of four independent experiments. *p,0.02 vs control. #p,0.02 vs scrambled Control +
TWEAK.
doi:10.1371/journal.pone.0008955.g005
Figure 6. TWEAK induces nuclear translocation of p52 and RelB in vivo. A) p100/p52 immunohistochemistry 24 h following TWEAK or
vehicle injection. Nuclear p52 is observed in renal tubules from mice treated with TWEAK (arrows). Original magnification 6400. Detail 61000.
Pictures representative of 6/7 animals per group. B) RelB immunohistochemistry 24 h following TWEAK or vehicle injection. Nuclear RelB is observed
in tubules from mice treated with TWEAK (arrows). Original magnification 6400. Detail 61000. Controls for the technique are stained with non-
specific IgG. Nuclear staining is present in samples stained with specific anti-p100/52 and anti-RelB as compared with the isotype control. Pictures
representative of 6/7 animals per group.
doi:10.1371/journal.pone.0008955.g006
TWEAK and NFkB2 Pathway
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It was previously reported that TWEAK has a proinflammatory
effect dependent on the canonical NFkB pathway in cultured
tubular epithelial cells [9]. In these cells TWEAK induces the
RelA-dependent synthesis of MCP-1, IL-6 and RANTES and, in
addition, TWEAK induces sustained NFkB activation [9]. We
now provide evidence that supports the notion that in tubular
epithelium TWEAK induces the sequential activation of two
separate signaling cascades for NFkB that promote the transcrip-
tion of different sets of genes. Initially canonical activation of RelA
promotes the release of MCP-1 and RANTES [9]. In tubular
cells TWEAK also activates the non-canonical NFkB pathway
requiring NIK, p100 processing and RelB and leading the
synthesis of CCL21. Thus CCL21 is identified as a TWEAK-
regulated gene in tubular cells in culture and in vivo. This
information identifies a new signaling cascade in tubular cell injury
and will help develop new targets for therapeutic intervention [9].
NFkB activates the transcription of different genes with
specificity and kinetics that vary in a gene-, stimulus- and cell-
specific manner. Delayed kinetics of gene transcription may be due
to involvement of the non-canonical NFkB pathway or to
decreased DNA accessibility [18,36].
Delayed NFkB-dependent gene transcription may be the
consequence of NFkB activation through the non-canonical
pathway [18]. TWEAK was observed to induce non-canonical
Figure 7. TWEAK modulates kidney CCL21 expression in vivo. A) TWEAK treatment of healthy mice increases kidney CCL21a mRNA at 24 h.
RNA obtained from the whole kidney. Real time RT-PCR. Mean 6SEM of 6/7 animals per group. *p,0.05 vs control 24 h. B) Increased kidney CCL21
protein induced by TWEAK as assessed by Western blot. Mean 6 SEM of 6/7 animals per group. *p,0.05 vs control 24 h. C) CCL21 protein localized
to tubular epithelium of kidneys 24 h following TWEAK injection. Original magnification 6200. Detail 6400. Controls for the technique are stained
with non-specific IgG. D) Quantification of CCL21 staining as mean 6 SEM of 5 animals per group. *p,0.04 vs control.
doi:10.1371/journal.pone.0008955.g007
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this activation were studied and it is unknown if the pathway is
active in epithelial cells [24]. Indeed no targets of non-canonical
NFkB by TWEAK have been previously characterized. There is
more information on NFkB2 targets in lymphoid cells. Thus,
LTbetaR ligation induces CCL21/SLC, BLC, ELC, SDF1 and
BAFF expression in the spleen through the non-canonical pathway
of NFkB activation [19]. The kinetics of RelA, RelB and p52
activation by LtbetaR ligation in spleen were similar to those
observed with TWEAK treatment of tubular cells in the present
paper [19]. Peripheral lymph node expression of CCL21 was
down regulated in NFkB22/2 mice, suggesting the requirement
for NFkB2 for its expression [12]. Of these potential NFkB2
targets we chose CCL21 for further study. CCL21 is a high affinity
ligand for chemokine receptor 7 (CCR7). Activation of CCR7 is
chemotactic for thymocytes, T cells, mature dendritic cells, and, to
a lesser extent, B cells [39]. CCL21 plays a role in mediating
homing of lymphocytes to secondary lymphoid organs. In addition
it induces chemotaxis and proliferation in mesangial cells [39,40].
Moreover, CCR7-positive fibrocytes migrate into the kidney in
response to SLC/CCL21 and contribute to kidney fibrosis
induced by unilateral ureteral obstruction in mice [26]. CCL21
also binds to the chemokine receptors CCR11 and CXCR3 [34].
While CCL21 expression by high endothelial venules (HEV)-like
vessels was previously emphasized, most CCL21 was expressed
outside these vessels [26]. CCL21 had been previously reported to
be expressed by podocytes and endothelial lymphoid cells [40,41].
However, its expression by tubular cells was poorly characterized
and the factors that regulate renal CCL21 expression had not been
identified.
In cultured tubular cells TWEAK induced a delayed expression
of CCL21. This contrasts to the early peak (3 h) of MCP-1 and
IL-6 gene expression which was abolished by the RelA inhi-
bitor parthenolide [9]. In vivo TWEAK administration increased
Figure 8. Absence or antagonism of TWEAK decreases RelB and p52 nuclear translocacion in AKI. AKI was induced by a single folic acid
overdose. This model is characterized by increased renal tubular expression of TWEAK and Fn14 [9,10]. A) RelB immunohistochemistry, B) p52
immunohistochemistry. Note nuclear cell localization of RelB and p52 in mice with acute kidney injury (AKI) at 24 h (arrows). TWEAK deficiency or
antibody mediated inhibition decreases RelB and p52 positive nuclei. Controls for the technique are stained with non-specific IgG. Original
magnification 6400. Detail 61000. Pictures representative of 5 animals per group.
doi:10.1371/journal.pone.0008955.g008
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contrast to the early (4 h) increase in RelA-dependent genes MCP-
1 and Il-6 under the same experimental conditions [9]. The
temporal pattern of CCL21 mRNA expression in vitro and in vivo
was reminiscent of the delayed expression of RANTES in tubular
cells. A delayed access of RelA to DNA has been implicated in the
delayed induction of RANTES mRNA [36]. When access to DNA
is delayed, sustained RelA availability that persists up to when
DNA has become accessible for transcription is required [36].
RANTES induction by TWEAK shared with MCP-1 its response
to the RelA inhibitor parthenolide [9]. We now show persistent
low level RelA binding to DNA (up to 24 h) in tubular cells
stimulated with TWEAK. Taken together these data are consistent
with the hypothesis that the canonical NFkB pathway is
responsible for the delayed RANTES upregulation in TWEAK-
stimulated tubular cells. However, contrary to the findings with
RANTES [9], the expression of CCL21 was not prevented by
parthenolide. Functional studies indicate that the delayed induc-
tion of CCL21 is dependent on the delayed activation of the non-
canonical NFkB pathway and requires NIK, NFkB2 processing
and RelB. To the best of our knowledge CCL21 is the first non-
canonical NFkB2 target identified in tubular cells. Since TNF did
Figure 9. Absence or antagonism of TWEAK decreases CCL21 in AKI. A) TWEAK deficiency or anti-TWEAK antibodies decrease kidney CCL21a
mRNA in AKI at 24 h following injury. Real time RT-PCR. Mean 6SEM of 6/7 animals per group. *p,0.02 vs control, #p,0.05 vs AKI, {p,0.05 vs AKI +
isotype IgG. B) Total kidney CCL21 protein expression in AKI at 24 h following renal injury. Measured by Western blot. Mean 6 SEM of 6/7 animals per
group. *p,0.03 vs control, #p,0.05 vs AKI, {p,0.05 vs AKI + sotype IgG. Representative Western blot showing CCL21 protein expression in AKI
model. C) CCL21 immunohistochemistry. Note epithelial cell localization of increased CCL21 expression in mice with AKI, when compared with
healthy control or mice with AKI treated with anti-TWEAK. Original magnification6200. Detail6400. Controls for the technique are stained with non-
specific IgG. D) Quantification of CCL21 as mean 6 SEM of 6/7 animals per group. *p,0.004 vs control, #p,0.002 vs AKI.
doi:10.1371/journal.pone.0008955.g009
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that clearly upregulate MCP-1, Il-6 and RANTES [9], our
findings identify renal actions of TWEAK that are non-redundant
to those of TNF. This emphasizes the importance of unraveling
the role of TWEAK in renal disease. The in vivo observation of
increased CCL21 during AKI as well as the modulation by
TWEAK antagonism of nuclear translocation of components of
the non-canonical NFkB pathway, CCL21 expression and T cell
infiltration suggests that this might be a clinically relevant
observation. An essential role for CCL21 in the recruitment of
effector T cells to peripheral tissues was established in a model or
airway challenge [33]. Interestingly, while microarray analysis did
not differentially cluster the transcriptomic responses to TWEAK
and TNF, it did disclose upregulation of CCL19, another NFkB2-
regulated cytokine, only by TWEAK.
There is scarce prior information on the non-canonical NFkB
pathway in kidney injury. Both p52 and RelB were part of NFkB
DNA-binding complexes found in the kidney in mice with
unilateral ureteral obstruction [42]. Reperfusion injury is associ-
ated with NIK phosphorylation [43]. Changes in the expression of
NIK and RelB, including increased cytosolic NIK and RelB
expression, were found in kidneys from experimental diabetic
nephropathy animals [44]. However, the factors activating this
pathway were not characterized, and no downstream renal targets
had been identified in these studies.
In summary, we have described TWEAK as an activator of the
non-canonical NFkB pathway in tubular cells, and identified one
of its target genes in these cells, the chemokine CCL21. To our
knowledge this is the first time that stimuli modulating non-
canonical NFkB activation in tubular cells have been explored,
and the first time that TWEAK has been linked to CCL21
regulation via this pathway. Activation of the non-canonical
pathway may contribute to the deleterious effect of TWEAK in
AKI, as anti-TWEAK antibodies decrease renal inflammation and
improve renal function [9]. This information may be relevant for
developing new therapeutic approaches to kidney disease.
Figure 10. Antagonism or absence of TWEAK decreases CD3
+ lymphocytes in AKI. The increased number of interstitial lymphocytes
stained with anti-CD3 (arrows) in AKI kidneys was reduced by anti-TWEAK antibody treatment or in TWEAK KO mice. Original magnification 6200.
Controls for the technique are stained with non-specific Ig. Quantification as mean 6 SEM of 6/7 animals per group. *p,0.0001 vs control, #p,0.001
vs AKI, {p,0.002 vs AKI + Isotype IgG.
doi:10.1371/journal.pone.0008955.g010
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